文献速递前列腺增生与排尿功能障碍前列腺癌

基线PSA可预测轻度或无下尿路症状男性新发LUTS:REDUCE研究事后分析

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-05-23

REDUCE研究4年事后分析纳入1534例基线IPSS<8的轻度或无下尿路症状(LUTS)男性,评估基线PSA是否独立预测新发LUTS。结果显示PSA每升高1 ng/mL,新发LUTS风险增加8%(多因素HR 1.08,p=0.040);PSA 6-10 ng/mL较2.5-4 ng/mL风险增加68%(HR 1.68,p=0.016)。

要点

  • 轻度或无LUTS男性中,基线PSA升高与新发LUTS风险独立相关。
  • PSA 6-10 ng/mL者较2.5-4 ng/mL者新发LUTS风险增加68%。
  • PSA 4.1-6 ng/mL者较2.5-4 ng/mL者新发LUTS风险增加60%。

核心结论

  • 基线PSA升高的轻度或无LUTS男性,新发LUTS风险增加,推测与良性前列腺增生相关。

研究设计与样本

  • REDUCE研究4年事后分析,纳入1534例基线IPSS<8的轻度或无LUTS男性。

主要发现

  • 4年内196例进展为新发LUTS,其中50.5%接受药物治疗、9%接受手术、40.5%出现新症状。
  • PSA作为连续变量,单因素分析HR 1.09(p=0.019),多因素分析HR 1.08(p=0.040)。
  • 基线PSA 6-10 ng/mL较2.5-4 ng/mL,校正后HR 1.68(p=0.016)。
  • 基线PSA 4.1-6 ng/mL较2.5-4 ng/mL,校正后HR 1.60(p=0.032)。

关键数值与推荐

  • 新发LUTS定义为首次报告接受药物治疗、手术或持续有临床意义的症状(两次IPSS>14)。
  • 多因素模型校正年龄、前列腺体积和基线IPSS。

临床怎么用

  • 对轻度或无LUTS男性,基线PSA较高者可提示新发LUTS风险增加,可加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between baseline prostate-specific antigen (PSA) and development of lower urinary tract symptoms (LUTS) in asymptomatic and mildly symptomatic men is unclear. We sought to determine if PSA predicts incident LUTS in these men. METHODS: A post-hoc analysis of the 4-year REDUCE study was performed to assess for incident LUTS in 1534 men with mild to no LUTS at baseline. The primary aim was to determine whether PSA independently predicted incident LUTS after adjusting for the key clinical variables of age, prostate size, and baseline International prostate symptom score (IPSS). Incident LUTS was defined as the first report of medical treatment, surgery, or sustained clinically significant symptoms (two IPSS >14). Cox proportional hazards, cumulative incidence curves, and the log-rank test were used to test our hypothesis. RESULTS: A total of 1534 men with baseline IPSS <8 were included in the study cohort. At baseline, there were 335 men with PSA 2.5-4 ng/mL, 589 with PSA 4.1-6 ng/mL, and 610 with PSA 6-10 ng/mL. During the 4-year study, 196 men progressed to incident LUTS (50.5% medical treatment, 9% surgery, and 40.5% new symptoms). As a continuous variable, higher PSA was associated with increased incident LUTS on univariable (HR 1.09, p = 0.019) and multivariable (HR 1.08, p = 0.040) analysis. Likewise, baseline PSA 6-10 ng/mL was associated with increased incident LUTS vs. PSA 2.5-4 ng/mL in adjusted models (HR 1.68, p = 0.016). This association was also observed in men with PSA 4.1-6 ng/mL vs. PSA 2.5-4 ng/mL (HR 1.60, p = 0.032). CONCLUSIONS: Men with mild to no LUTS but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Patel DN, Feng T, Simon RM, et al. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018. PMID: 29795141. doi:10.1038/s41391-018-0044-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。